Preclinical and translational studies have demonstrated that DRD2 agonists attenuate aberrant angiogenesis, promote vascular normalization, and mitigate VEGF-A-induced vascular leakage in diverse pathological contexts, including malignancy, ovarian hyperstimulation syndrome, endometriosis, and inflammatory lung injury. This evidence concerns the gene DRD2 and ovarian hyperstimulation syndrome.